EKR Therapeutics, Inc. Names Two Independent Directors and Reaffirms Board of Directors to Lead Company Growth in the Critical Care Sector
Published: Dec 15, 2011
BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a privately held specialty pharmaceutical company focused on providing critical care products to the hospital marketplace, has announced the appointment of Robert S. Whitehead and Joseph M. Mahady to the EKR Board as Independent Directors. On October 21, 2011, Robert P. Roche, Jr. was previously named as an Independent Director. In addition, all previous Board Members were reelected at EKR’s November 8th Annual Meeting of Stockholders.